Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company specializing in the production of pharma intermediates and active pharmaceutical ingredients (APIs). It manufactures high-purity pharmaceutical intermediates used in API production and APIs that are utilized in medicines, nutraceuticals, personal care, and animal health products. The company’s offerings are produced in compliance with Indian and international pharmacopeia standards such as IP, BP, EP, JP, and USP. Along with manufacturing APIs and intermediates to global standards, Anlon Healthcare also provides custom manufacturing for complex chemicals, focusing on exceeding purity standards and minimizing impurities to meet customer-specific requirements. The company has obtained Drug Master File (DMF) approval from regulatory authorities including ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. It has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals. Its portfolio comprises 65 commercialized products, 28 at the pilot stage, and 49 undergoing laboratory testing. To ensure consistent product quality, the company follows rigorous testing and process improvements, supported by four laboratories and a 34-member technical team, which includes 24 science graduates. The company’s product range includes pharmaceutical intermediates such as Cyanoethylbenzoic acid, Ketonitrile, and Methyldesloratadine, which serve as key starting materials or advanced intermediates for API manufacturing. Its APIs are essential components in pharmaceutical products, delivering therapeutic effects and being used in various formulations like tablets, capsules, ointments, and syrups, as well as in nutraceuticals, personal care, and veterinary products. As of January 31, 2025, Anlon Healthcare employed 105 people (excluding trainees) along with 8 contract workers.
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company specializing in the production of pharma intermediates and active pharmaceutical ingredients (APIs). It manufactures high-purity pharmaceutical intermediates used in API production and APIs that are utilized in medicines, nutraceuticals, personal care, and animal health products. The company’s offerings are produced in compliance with Indian and international pharmacopeia standards such as IP, BP, EP, JP, and USP. Along with manufacturing APIs and intermediates to global standards, Anlon Healthcare also provides custom manufacturing for complex chemicals, focusing on exceeding purity standards and minimizing impurities to meet customer-specific requirements. The company has obtained Drug Master File (DMF) approval from regulatory authorities including ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. It has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals. Its portfolio comprises 65 commercialized products, 28 at the pilot stage, and 49 undergoing laboratory testing. To ensure consistent product quality, the company follows rigorous testing and process improvements, supported by four laboratories and a 34-member technical team, which includes 24 science graduates. The company’s product range includes pharmaceutical intermediates such as Cyanoethylbenzoic acid, Ketonitrile, and Methyldesloratadine, which serve as key starting materials or advanced intermediates for API manufacturing. Its APIs are essential components in pharmaceutical products, delivering therapeutic effects and being used in various formulations like tablets, capsules, ointments, and syrups, as well as in nutraceuticals, personal care, and veterinary products. As of January 31, 2025, Anlon Healthcare employed 105 people (excluding trainees) along with 8 contract workers.
